eCTD modules and submissions under FDA and EMA format rules
eCTD is the electronic format for a medicine's regulatory dossier. It has five modules, differs from CTD, and FDA still accepts 3.2.2 and 4.0.
eCTD, the electronic Common Technical Document, is the electronic submission format for a medicine's regulatory dossier. The CTD organises that content into five modules, and the eCTD implements the structure electronically (ICH, EMA). Following the CTD layout alone does not produce an eCTD package, so confirm the receiving authority's supported version before you publish.
The five eCTD modules
ICH organises the CTD into five modules. Module 1 is region-specific, and Modules 2 to 5 are intended to be common across regions (ICH). The eCTD keeps that same five-module structure.
| Module | Content |
|---|---|
| Module 1 | Administrative and prescribing information, specific to each region |
| Module 2 | CTD summaries: quality, nonclinical and clinical overviews and summaries |
| Module 3 | Quality |
| Module 4 | Nonclinical study reports |
| Module 5 | Clinical study reports |
Why Module 1 is different
Module 1 contains region-specific administrative and prescribing information. Modules 2 to 5 are intended to be common, but that does not remove regional requirements (ICH). Check the receiving authority's Module 1 specification rather than treating the dossier as identical across markets. In the EU, EMA made the updated EU Module 1 v3.1.1 mandatory from 1 December 2025 (EMA).
How eCTD differs from CTD
The CTD is about content and organisation. It tells you what goes in each module and section. The eCTD is the electronic package used to transmit that content.
EMA describes the eCTD as a harmonised technical solution for implementing the CTD electronically. For version 3.2.2, it describes PDF documents stored in a defined directory structure and accessed through an XML backbone (EMA). PDF is the generally accepted format. Other formats are exceptionally accepted in specific cases (EMA).
A folder of PDFs, a merged PDF or a Word template is not an eCTD submission on its own. The technical structure around the documents is part of the format. Do not carry those 3.2.2 directory details over to version 4.0.
Later submissions use the same electronic format. FDA describes eCTD for applications, amendments, supplements and reports as well as the first package (FDA). That package is the electronic dossier. It is the files plus the technical structure, not a one-time PDF bundle.
FDA eCTD guidance and eCTD 4.0
FDA describes eCTD as the standard format for submitting applications, amendments, supplements and reports to CDER and CBER (FDA). FDA's standards page records the historical requirement dates: 5 May 2017 for NDAs, ANDAs and BLAs, and 5 May 2018 for commercial INDs and master files (FDA). Those dates are when eCTD itself became required. They are not eCTD 4.0 mandates.
The main eCTD page lists the covered submissions as NDAs, ANDAs, BLAs, commercial INDs and all subsequent submissions to those applications, including amendments, supplements and reports. It also lists master files such as DMFs that are submitted to an IND, NDA, ANDA or BLA (FDA). FDA lists noncommercial INDs as optional but encouraged, including investigator-sponsored and expanded-access INDs. The same optional list covers submissions for blood and blood components, including source plasma, and Type III master files (FDA). The 4.0 dates below are separate from those requirement dates.
- On 16 September 2024, CDER and CBER began accepting new regulatory applications in eCTD 4.0 (FDA).
- From 16 October 2026, forward compatibility is supported for NDA, BLA, ANDA, IND and master files. Applications originally submitted in 3.2.2 can continue in 4.0 (FDA).
- The FDA page is marked content current as of 29 October 2026. As checked on 12 November 2026, it has not announced a 4.0-only date. It supports both 3.2.2 and 4.0 and says it will give advance notice before supporting 4.0 alone (FDA).
Older advice that an existing 3.2.2 application cannot move to 4.0 at FDA has been out of date since 16 October 2026 (FDA).
EMA eCTD and the EU 4.0 timeline
In the EU, eCTD is mandatory for marketing authorisation submissions in the centralised, decentralised and mutual recognition procedures (EMA). National procedures have a stepwise introduction (EMA). Alongside the EU Module 1 v3.1.1 update, validation criteria v8.2 also became mandatory from 1 December 2025 (EMA). Those version numbers are separate from eCTD 4.0.
EMA's announced 4.0 adoption steps are scoped to new marketing authorisation applications (MAAs) for centrally authorised products (CAPs) (EMA). During the transition, eCTD 3.2.2 continues to be accepted while applicants prepare for 4.0.
| Milestone | What EMA has announced |
|---|---|
| 22 December 2025 | Optional eCTD 4.0 submission of new CAP MAAs |
| Transition period | eCTD 3.2.2 continues to be accepted |
| Q1 2027 | Strongly recommended use of 4.0 for new CAP MAAs |
| Q1 2028 | Announced mandatory use for new CAP MAAs |
The Q1 2027 step is strongly recommended use, not a requirement. And the Q1 2028 milestone applies to new CAP MAAs, not to every EU dossier, every procedure type or UK submissions. EMA gives quarters rather than exact days. Check its eCTD 4.0 page for implementation updates.
Before any 4.0 submission, EMA requires applicants to contact its eCTD 4.0 team. The EU 4.0 validation criteria v1.1 apply from 15 July 2026 (EMA). EMA also says forward compatibility in the EU depends on testing and readiness assessments, so for existing EU dossiers, follow EMA's announcements rather than assuming the FDA position applies.
eCTD submissions in the UK and India
MHRA guidance says UK marketing authorisation applications should use eCTD, that technical validation aligns with ICH standards and eCTD 3.2 regional requirements, and that using a validation tool is recommended. The page was last updated on 2 October 2026 (MHRA). EMA's timetable does not apply in the UK. For eCTD 4.0 in the UK, check MHRA's guidance for any acceptance date.
For readers in India, the five-module CTD structure is the shared ICH foundation (ICH). Before preparing a dossier for India, confirm the current CDSCO submission format. A US or EU eCTD date does not set an Indian acceptance date.
eCTD publishing software, validators and viewers
Publishing software, validators and viewers are often named together. The jobs differ.
- An eCTD publisher assembles the documents and metadata into the electronic submission package the authority expects, including the structure described in EMA's eCTD documentation (EMA).
- A validator checks the package against the applicable technical specification and regional validation criteria. MHRA recommends a validation tool, and FDA lists validation criteria separately on its standards pages (MHRA, FDA).
- A viewer lets you open and navigate the documents and structure in that electronic package (EMA).
These are functional descriptions, not a vendor comparison. When choosing software, check which functions and regional specifications it supports. Use validation to check the package against the current criteria. Passing that check is not scientific approval.
A short preparation checklist
- Identify the receiving authority and the application type.
- Confirm which eCTD version that authority supports for that application type, and which regional Module 1 applies.
- Assemble the content for Modules 1 to 5 in line with ICH M4 and the regional guidance.
- Validate the package against the authority's current validation criteria.
- Review the output in a viewer before submitting.
RegAffairs AI's answer on eCTD explains the CTD distinction with citations.